Luprolide Acetate (Lupron®, Eligard®)

BCommon name: Luprolide Acetate
Brand name: Lupron®, Eligard®
 

What is Luprolide Acetate?

Luprolide Acetate is a hormonal therapy medication that is used in the palliative treatment of advanced prostate cancer. It works by slowing or stopping the production of testosterone to stop or slow prostate cancer cells from growing and reproducing.
 

How is Luprolide Acetate administered?

Luprolide Acetate is administered by subcutaneous injection.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received luprolide acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Breast tenderness
  • Decreased libido
  • Diarrhea
  • Fatigue
  • Headaches
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea / vomiting
  • Osteoporosis (weakened bones)
  • Weight gain
 

 Is Luprolide Acetate covered in my province or territory?

Luprolide acetate (Eligard®) is covered by all provincial/territorial drug programs.

​Luprolide acetate (Lupron®​) is covered by provincial drug programs in:
  • Alberta​
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Quebec
  • Saskatchewan
​Luprolide acetate (Lupron®) is not covered by provincial drug programs in:
  • Northwest Territories
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Yukon
 

Last Reviewed: July 2017

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More

Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More


Click here for news archive